Cargando…

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models

SIMPLE SUMMARY: The cyclin E/CDK2 complex may present a promising target axis for the treatment of triple-negative breast cancers (TNBC); however, therapeutically relevant doses of CDK2 inhibitors have been associated with toxicities. Here, we report that the suboptimal dosing of the CDK 2, 7 and 9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Anthony, Chenoweth, Alicia M., Quist, Jelmar, Sow, Heng Sheng, Malaktou, Christina, Ferro, Riccardo, Hoffmann, Ricarda M., Osborn, Gabriel, Sachouli, Eirini, French, Elise, Marlow, Rebecca, Lacy, Katie E., Papa, Sophie, Grigoriadis, Anita, Karagiannis, Sophia N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322647/ https://www.ncbi.nlm.nih.gov/pubmed/35884422 http://dx.doi.org/10.3390/cancers14143361

Ejemplares similares

Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification
por: Quist, Jelmar, et al.
Publicado: (2021)

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
por: Harris, Robert J., et al.
Publicado: (2021)

Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication
por: Liu, Fangfang, et al.
Publicado: (2021)

Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases
por: Ng, Joseph C F, et al.
Publicado: (2019)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer
por: Soady, Kelly J, et al.
Publicado: (2015)

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
por: Patel, Nirmesh, et al.
Publicado: (2018)

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B
por: Akre, Monica K., et al.
Publicado: (2016)

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
por: Adams, Rebecca, et al.
Publicado: (2022)

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
por: Willsmore, Zena N., et al.
Publicado: (2021)

Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
por: MALAS, SADEK, et al.
Publicado: (2014)

Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician
por: Adams, Rebecca, et al.
Publicado: (2021)

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
por: Tovey, Holly, et al.
Publicado: (2023)

Adipose-enriched peri-tumoral stroma, in contrast to myofibroblast-enriched stroma, prognosticates poorer survival in breast cancers
por: Lau, Hannah Si Hui, et al.
Publicado: (2023)

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
por: Osborn, Gabriel, et al.
Publicado: (2021)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
por: Chiaruttini, Giulia, et al.
Publicado: (2017)

Drug repurposing and prediction of multiple interaction types via graph embedding
por: Amiri Souri, E., et al.
Publicado: (2023)

CDK-Mediator and FBXL19 prime developmental genes for activation by promoting atypical regulatory interactions
por: Feldmann, Angelika, et al.
Publicado: (2020)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Utilizing Immunocytokines for Cancer Therapy
por: Runbeck, Erin, et al.
Publicado: (2021)

BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis
por: Singh, Priyanka, et al.
Publicado: (2021)

The nutrient-responsive CDK Pho85 primes the Sch9 kinase for its activation by TORC1
por: Deprez, Marie-Anne, et al.
Publicado: (2023)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
por: Schedin, Troy B., et al.
Publicado: (2018)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

The mechanism of the triple aryne–tetrazine reaction cascade: theory and experiment
por: Suh, Sung-Eun, et al.
Publicado: (2018)

B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge
por: Egbuniwe, Isioma U., et al.
Publicado: (2022)

Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer
por: Amiri Souri, E., et al.
Publicado: (2021)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
por: Li, Xiao, et al.
Publicado: (2022)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
por: Beykou, Melina, et al.
Publicado: (2022)

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients
por: Karagiannis, Panagiotis, et al.
Publicado: (2021)

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model
por: Williams, Iwan P., et al.
Publicado: (2019)

Triple aryne–tetrazine reaction enabling rapid access to a new class of polyaromatic heterocycles
por: Suh, Sung-Eun, et al.
Publicado: (2015)

Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
por: McCraw, Alex J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j7vresruf1m39v44demg1vpe35